Cargando…

mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy

mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Zhuoya, Tian, Yuying, Song, Jianxun, An, Guangwen, Yang, Penghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201022/
https://www.ncbi.nlm.nih.gov/pubmed/35720301
http://dx.doi.org/10.3389/fimmu.2022.887125
_version_ 1784728195218538496
author Deng, Zhuoya
Tian, Yuying
Song, Jianxun
An, Guangwen
Yang, Penghui
author_facet Deng, Zhuoya
Tian, Yuying
Song, Jianxun
An, Guangwen
Yang, Penghui
author_sort Deng, Zhuoya
collection PubMed
description mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a great deal of interest in the research and development of mRNA cancer vaccines. There has been progress in a number of key technologies, including mRNA production strategies, delivery systems, antitumor immune strategies, etc. These technologies have accelerated the progress and clinical applications of mRNA therapy, overcoming problems encountered in the past, such as instability, inefficient delivery, and weak immunogenicity of mRNA vaccines. This review provides a detailed overview of the production, delivery systems, immunological mechanisms, and antitumor immune response strategies for mRNA cancer vaccines. We list some mRNA cancer vaccines that are candidates for cancer treatment and discuss clinical trials in the field of tumor immunotherapy. In addition, we discuss the immunological mechanism of action by which mRNA vaccines destroy tumors as well as challenges and prospects for the future.
format Online
Article
Text
id pubmed-9201022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92010222022-06-17 mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy Deng, Zhuoya Tian, Yuying Song, Jianxun An, Guangwen Yang, Penghui Front Immunol Immunology mRNA therapy is a novel anticancer strategy based on in vitro transcription (IVT), which has potential for the treatment of malignant tumors. The outbreak of the COVID-19 pandemic in the early 21st century has promoted the application of mRNA technologies in SARS-CoV-2 vaccines, and there has been a great deal of interest in the research and development of mRNA cancer vaccines. There has been progress in a number of key technologies, including mRNA production strategies, delivery systems, antitumor immune strategies, etc. These technologies have accelerated the progress and clinical applications of mRNA therapy, overcoming problems encountered in the past, such as instability, inefficient delivery, and weak immunogenicity of mRNA vaccines. This review provides a detailed overview of the production, delivery systems, immunological mechanisms, and antitumor immune response strategies for mRNA cancer vaccines. We list some mRNA cancer vaccines that are candidates for cancer treatment and discuss clinical trials in the field of tumor immunotherapy. In addition, we discuss the immunological mechanism of action by which mRNA vaccines destroy tumors as well as challenges and prospects for the future. Frontiers Media S.A. 2022-06-02 /pmc/articles/PMC9201022/ /pubmed/35720301 http://dx.doi.org/10.3389/fimmu.2022.887125 Text en Copyright © 2022 Deng, Tian, Song, An and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Deng, Zhuoya
Tian, Yuying
Song, Jianxun
An, Guangwen
Yang, Penghui
mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
title mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
title_full mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
title_fullStr mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
title_full_unstemmed mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
title_short mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy
title_sort mrna vaccines: the dawn of a new era of cancer immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201022/
https://www.ncbi.nlm.nih.gov/pubmed/35720301
http://dx.doi.org/10.3389/fimmu.2022.887125
work_keys_str_mv AT dengzhuoya mrnavaccinesthedawnofaneweraofcancerimmunotherapy
AT tianyuying mrnavaccinesthedawnofaneweraofcancerimmunotherapy
AT songjianxun mrnavaccinesthedawnofaneweraofcancerimmunotherapy
AT anguangwen mrnavaccinesthedawnofaneweraofcancerimmunotherapy
AT yangpenghui mrnavaccinesthedawnofaneweraofcancerimmunotherapy